PCSA PCSA
Company Profile ↓Company Overview
PCSA (PCSA) is a publicly traded company listed on with a market capitalization of $5.63M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.00.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -62.08% |
| 6 Months: | -10.25% |
| 3 Months: | -17.67% |
| 1 Month: | +15.87% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)48.07 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 81.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | 0 | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 42.64K | 27.33K | 12.79K | 9.03K | 15.55K | 5.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.85M | 3.95M | 3.49M | 3.70M | 3.33M |
| Operating Income | - | - | - | - | - | - | - | - | - | -233.94K | -280.33K | -712.85K | - | -1.29M | -1.43M | -1.06M | -882.52K | -1.14M | -1.00M | -986.12K | -801.99K | -2.96M | -2.19M | -3.46M | -3.11M | -3.23M | -5.17M | -6.06M | -4.11M | -2.71M | -2.17M | -2.81M | -3.08M | -3.42M | - | -2.85M | -3.95M | -3.49M | -3.70M | -3.33M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.85M | -3.95M | -3.49M | -3.70M | -3.33M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.83M | -3.93M | -3.44M | -3.36M | -3.38M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | - | 0 |
| Net Income | -851.22K | -791.95K | -644.61K | -2.05M | -295.74K | -280.95K | -574.41K | -827.37K | -234.34K | -232.44K | -278.44K | -711.57K | -633.86K | -1.10M | -1.21M | -852.82K | -750.83K | -969.08K | -863.52K | -874.34K | -733.41K | -3.07M | -2.10M | -3.16M | -2.99M | -3.23M | -5.16M | -6.02M | -4.02M | -2.61M | -2.08M | -2.73M | -3.01M | -3.38M | - | -2.83M | -3.93M | -3.44M | -3.36M | -3.38M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.32 | -0.37 | -3.53 | -1.94 | -1.54 | -1.11 | -1.01 | -1.03 | - | -7.58 | -6.25 | -1.75 | - | -1.29 |
| R&D Expense | 68.50K | 11.73K | 11.74K | 10.79K | 1.71K | - | 5.70K | 574 | - | 139.92K | 160.87K | 457.63K | - | 821.39K | 1.08M | 611.61K | 484.75K | 726.90K | 584.98K | 501.77K | 427.11K | 532.59K | 1.48M | - | - | 2.04M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 192.15K | 312.48K | 107.24K | 113.42K | 5.00K | - | - | - | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 58.89K | 124.48K | 40.41K | -12.45K | 5.00K | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | 20.26M | 11.46M | 12.05M | 13.99M |
| Operating Income | - | - | - | - | -1.92M | -1.80M | -4.52M | -3.94M | -15.14M | - | -20.26M | -11.46M | -12.05M | -13.99M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | -19.47M | -11.46M | -12.05M | -13.99M |
| Interest Expense | - | - | - | - | - | - | - | - | - | 362 | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | -27.42M | -11.12M | -11.85M | -13.56M |
| Tax Provision | - | - | - | - | - | - | - | - | - | -530.61K | 0 | 0 | - | 0 |
| Net Income | -2.44M | -3.07M | -4.53M | -3.35M | -1.92M | -1.86M | -3.77M | -3.36M | -14.41M | - | -27.42M | -11.12M | -11.85M | -13.56M |
| Diluted EPS | - | - | - | - | -0.07 | -0.06 | - | - | - | - | -851.25 | -212.00 | -96.78 | -10.36 |
| R&D Expense | 448.03K | 267.06K | 178.09K | 29.25K | 1.54M | 964.16K | 3.09M | 2.32M | 3.17M | 6.88M | 11.49M | 5.80M | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 3.88M | 2.94M | 2.55M | 104.32K | 2.36M | 2.98M | 12.48M | 10.88M | 25.21M | - | 8.62M | 5.79M | 3.23M | 7.81M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | 8.39M | 5.63M | 1.88M | 5.67M |
| Cash & Equivalents | 2.79M | 1.02M | 186.86K | 21.23K | 2.09K | 1.07M | 2.85M | 1.74M | 691.54K | 15.42M | - | 6.50M | 4.71M | 1.19M | 5.54M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | 70.27K | 0 | - | - | - |
| Total Liabilities | - | 1.32M | 1.27M | 1.34M | 2.08M | 97.69K | 2.61M | 2.78M | 2.87M | 2.27M | - | 1.15M | 797.48K | 1.53M | 2.24M |
| Current Liabilities | - | 715.65K | 1.12M | 843.86K | 2.08M | 97.69K | 2.60M | 645.70K | 1.19M | 1.22M | - | 998.56K | 730.58K | 1.53M | 2.24M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | 229.45K | 150.55K | 73.51K | 0 |
| Total Equity | - | 2.56M | 1.67M | 1.21M | -85.70K | -2.27M | 373.16K | 9.70M | 8.01M | 22.94M | - | 7.47M | 4.99M | 1.70M | 5.58M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | 32.27K | 51.64K | 148.31K | 2.57M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.89M | -2.54M | -2.69M | -871.91K | -2.16M | -1.65M | -3.71M | -2.75M | -3.14M | - | -9.61M | -8.06M | -11.25M | -11.39M |
| Investing Cash Flow | -334.34K | -27.67K | -44.94K | 40.20K | -1.04M | 1.00M | -22.28K | - | - | - | 0 | -2.78K | -3.24K | -850.00K |
| Financing Cash Flow | 453.38K | 1.73M | 2.57M | 821.10K | 4.27M | 2.43M | 2.62M | 1.70M | 17.87M | - | -388.84K | 6.27M | 7.73M | 16.58M |
| Capital Expenditure | -334.34K | -27.67K | -11.01K | -1.40K | -23.77K | -20.62K | - | - | - | - | - | -2.78K | -3.24K | -850.00K |
| Free Cash Flow | -2.23M | -2.57M | -2.70M | -873.30K | -2.18M | -1.68M | - | - | - | - | -9.61M | -8.07M | -11.25M | -12.24M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | -9.99M | -1.80M | -3.51M | 4.35M |
| Dividends Paid | - | - | 45.59K | 42.94K | - | - | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 30.6% | 39.8% | 37.7% | -11.0% | 100.0% | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | -38,430.4% | - | - | - | - | - | - | - | - | - |
| Net Margin % | -1,270.2% | -982.0% | -4,220.7% | -2,957.2% | -38,341.3% | - | - | - | - | - | - | - | - | - |
| ROE % | -95.2% | -183.7% | -374.7% | 3,913.7% | 84.6% | -497.5% | -38.8% | -41.9% | -62.8% | - | -367.1% | -222.9% | -698.6% | -243.2% |
| ROCE % | - | - | - | - | -84.8% | -470.5% | -38.2% | -40.6% | -63.1% | - | -265.8% | -226.6% | -710.3% | -250.8% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PCSA
Processa Pharmaceuticals Acquires Vidya Therapeutics and Secures $200 Million Financing to Advance BTK Inhibitor Pipeline
The acquisition transforms Processa’s pipeline with the addition of clinical-stage BTK inhibitor VT-7208, while a concurrent $200 million private placement is expected to fund development into 2029. Key Investor TakeawaysProcessa Pharmaceut…
PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREAS
Acquisition brings into Processa’s pipeline Vidya’s lead asset, VT-7208, a next-generation, CNS-penetrant, once-daily, oral potentially best-in-class Bruton’s tyrosine kinase inhibitor (BTKi) designed to overcome the efficacy and safety lim…
Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference
VERO BEACH, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies, today announced that George Ng, Chief Executive…
Alliance Entertainment and Processa Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FLORIDA / ACCESS Newswire / January 9, 2026 / RedChip Companies will air interviews with Alliance Entertainment Holding Corp. (Nasdaq:AENT) and Processa Pharmaceuticals, Inc. (Nasdaq:PCSA) on the RedChip Small Stocks, Big Money™sho…
Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study
Interim safety and efficacy data to be reported in Q1 VERO BEACH, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) ther…
Processa Pharmaceuticals and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESS Newswire / December 26, 2025 / RedChip Companies will air interviews with Processa Pharmaceuticals, Inc. (Nasdaq:PCSA) and 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) on the RedChip Small Stocks, Big Money™ show, a s…
PCSA — Frequently Asked Questions
What is the current share price of PCSA?
As of 2026-08-05 17:25 PDT, PCSA trades at $2.19 on NASDAQ/NYSE. Its 52-week range is $1.85 to $11.98.
What is the market capitalisation of PCSA?
PCSA has a market capitalisation of $5.63M on NASDAQ/NYSE.
What is the P/E ratio of PCSA?
PCSA trades at a trailing price-to-earnings (P/E) ratio of -0.21. Its price-to-book (P/B) ratio is 1.01.
Is PCSA a good stock to buy?
This page provides a data-driven analysis of PCSA, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.